UroGen Pharma Ltd.
UroGen Pharma Ltd. is listed today as UroGen Pharma Ltd.: market value, financials and filings are on its company page.
Funding rounds
0 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Jul 2023 | $120 M | Private placement after listing | $50 to $250 million | equity, options | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
As the listed company UroGen Pharma Ltd., its revenue in fiscal 2025 came from these product and service lines: Jelmyto $93.99 million (86%), Zusduri $15.80 million (14%).
Annual report (SEC XBRL) · Dec 2025
UroGen Pharma Ltd. chose not to state its revenue in its newest notice of a funding round (Aug 2023).
SEC Form D · Aug 2023
The industry group it chose in its notices: Pharmaceuticals.
SEC Form D · Aug 2023
Products and services#
No products or services of UroGen Pharma Ltd. are on record.
Investors#
No investor of UroGen Pharma Ltd. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete.
Largest shareholders today
Institutions holding UroGen Pharma Ltd. shares, as of Sep 30, 2026.
- RTW Investments, LP$185 M9.26%
- BlackRock, Inc.$126 M6.34%
- Kynam Capital Management, LP$99 M4.96%
- Jefferies Financial Group Inc.$89 M4.48%
- Morgan Stanley$88 M4.43%
- Acorn Capital Advisors, LLC$67 M3.36%
- Opaleye Management Inc.$59 M2.94%
- American Century Companies Inc$56 M2.80%
- D. E. Shaw & Co., Inc.$52 M2.62%
- Silverarc Capital Management, LLC$47 M2.34%
- Orbimed Advisors LLC$40 M2.02%
- State Street Corp$40 M1.99%
- Frontier Capital Management Co LLC$38 M1.91%
- MPM Bioimpact LLC$37 M1.85%
- Goldman Sachs Group Inc$34 M1.73%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Don Kim | Executive officer | Aug 2023 |
| Elizabeth Barrett | Executive officer | Aug 2023 |
| Jason A. Smith | Executive officer | Aug 2023 |
| Mark A. Schoenberg, M.D. | Executive officer | Aug 2023 |
| Arie Belldegrun, M.D. | Director | Aug 2023 |
| Cynthia Butitta | Director | Aug 2023 |
| Dan Wildman | Director | Aug 2023 |
| Elizabeth Barrett | Director | Aug 2023 |
| Fred Cohen, M.D. | Director | Aug 2023 |
| James A. Robinson, Jr. | Director | Aug 2023 |
| Leana Wen, M.D., MSc | Director | Aug 2023 |
| Ran Nussbaum | Director | Aug 2023 |
| Stuart Holden, M.D. | Director | Aug 2023 |
Went public since 2017. Its SEC number is that of a company listed on a stock exchange.